Pure Global
NCT06218212

The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels

The Effect of Renastart Formula Supplementation on Serum Electrolytes in Children With Acute Kidney Injury
Ain Shams University·ClinicalTrials.gov·dietary supplementCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
Renastart formula
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Ain Shams University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Feb 12, 2022
End date
Jun 30, 2023
Enrollment
24 participants
Primary outcome

To evaluate the effectiveness and tolerability of Renastart formula in children with AKI and acute on top of CKD to correct and maintain normal serum levels of electrolytes.

Summary

This clinical trial will evaluate Renastart formula effectiveness in children with acute
 kidney injury (AKI) and acute on top of chronic kidney disease (CKD), in maintaining normal
 serum electrolytes levels without using electrolyte binders,24 patients will be recruited
 from Pediatric Nephrology Unit (PNU), Children's Hospital, Ain Shams University, they will be
 assigned randomly in to two arms, arm 1 including patients who will be treated by
 electrolytes binders, arm 2 including patients who will be treated by Renastart formula,
 after initial assessment serum electrolyte evaluation will be followed up monthly for 3
 months.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06218212
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06218212 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Completed. The study focuses on Acute Kidney Injury. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.